Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.

Abstract:

:The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Mahoney DH Jr,Cohen ME,Friedman HS,Kepner JL,Gemer L,Langston JW,James HE,Duffner PK,Kun LE

doi

10.1093/neuonc/2.4.213

keywords:

subject

Has Abstract

pub_date

2000-10-01 00:00:00

pages

213-20

issue

4

eissn

1522-8517

issn

1523-5866

journal_volume

2

pub_type

临床试验,杂志文章,多中心研究
  • Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

    abstract::Patients with the most common and aggressive form of high-grade glioma, glioblastoma multiforme, have poor prognosis and few treatment options. In 2 immunocompetent mouse brain tumor models (CT26-BALB/c and Tu-2449-B6C3F1), we showed that a nonlytic retroviral replicating vector (Toca 511) stably delivers an optimized...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor199

    authors: Ostertag D,Amundson KK,Lopez Espinoza F,Martin B,Buckley T,Galvão da Silva AP,Lin AH,Valenta DT,Perez OD,Ibañez CE,Chen CI,Pettersson PL,Burnett R,Daublebsky V,Hlavaty J,Gunzburg W,Kasahara N,Gruber HE,Jolly DJ,Robb

    更新日期:2012-02-01 00:00:00

  • REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.

    abstract:Background:Glioblastoma (GBM) is one of the most common, aggressive, and invasive human brain tumors. There are few reliable mechanism-based therapeutic approaches for GBM patients. The transcriptional repressor RE1 silencing transcriptional factor (REST) regulates the oncogenic properties of a class of GBM stem-like c...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now232

    authors: Marisetty AL,Singh SK,Nguyen TN,Coarfa C,Liu B,Majumder S

    更新日期:2017-04-01 00:00:00

  • ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.

    abstract::Glioma is the most common adult primary brain tumor. Its most malignant form, glioblastoma multiforme (GBM), is almost invariably fatal, due in part to the intrinsic resistance of GBM to radiation- and chemotherapy-induced apoptosis. We analyzed B-cell leukemia-2 (Bcl-2) anti-apoptotic proteins in GBM and found myeloi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor119

    authors: Day BW,Stringer BW,Spanevello MD,Charmsaz S,Jamieson PR,Ensbey KS,Carter JC,Cox JM,Ellis VJ,Brown CL,Walker DG,Inglis PL,Allan S,Reynolds BA,Lickliter JD,Boyd AW

    更新日期:2011-11-01 00:00:00

  • Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.

    abstract:BACKGROUND:The influence of survivin isoforms on outcome in glioblastoma is poorly understood. We analyzed the dominant anti-apoptotic transcript variants of survivin using expression data and modeled them in vivo to determine their impact on glioma formation and progression. METHODS:Using data from low- and high-grad...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou034

    authors: Doucette T,Latha K,Yang Y,Fuller GN,Rao A,Rao G

    更新日期:2014-09-01 00:00:00

  • Role of CX3CR1 signaling in malignant transformation of gliomas.

    abstract:BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa075

    authors: Lee S,Latha K,Manyam G,Yang Y,Rao A,Rao G

    更新日期:2020-10-14 00:00:00

  • Akt2 and Akt3 play a pivotal role in malignant gliomas.

    abstract::Akt, one of the major downstream effectors of phosphatidylinositol 3-kinase, is hyper-expressed and activated in a variety of cancers including glioblastoma. However, the expression profiles of the Akt isoforms Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma and their functional roles in malignant glioma are not well u...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nop026

    authors: Mure H,Matsuzaki K,Kitazato KT,Mizobuchi Y,Kuwayama K,Kageji T,Nagahiro S

    更新日期:2010-03-01 00:00:00

  • Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation.

    abstract:Background:Radiomics is a rapidly growing field in neuro-oncology, but studies have been limited to conventional MRI, and external validation is critically lacking. We evaluated technical feasibility, diagnostic performance, and generalizability of a diffusion radiomics model for identifying atypical primary central ne...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/noy021

    authors: Kang D,Park JE,Kim YH,Kim JH,Oh JY,Kim J,Kim Y,Kim ST,Kim HS

    更新日期:2018-08-02 00:00:00

  • HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.

    abstract:BACKGROUND:Diffuse midline glioma (DMG) is a pediatric malignancy with poor prognosis. Most children die less than one year after diagnosis. Recently, mutations in histone H3 have been identified and are believed to be oncogenic drivers. Targeting this epigenetic abnormality using histone deacetylase (HDAC) inhibitors ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz215

    authors: Capdevielle C,Desplat A,Charpentier J,Sagliocco F,Thiebaud P,Thézé N,Fédou S,Hooks KB,Silvestri R,Guyonnet-Duperat V,Petrel M,Raymond AA,Dupuy JW,Grosset CF,Hagedorn M

    更新日期:2020-04-15 00:00:00

  • Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

    abstract::Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox021

    authors: Cohen KJ,Jabado N,Grill J

    更新日期:2017-08-01 00:00:00

  • Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis.

    abstract:Background:Children with brain tumors treated with cranial radiation therapy (RT) often exhibit cognitive late effects, commonly associated with reduced white matter (WM) volume and decreased neurogenesis. The impact of radiation damage in particular regions or tissues on brain development as a whole has not been eluci...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox211

    authors: Beera KG,Li YQ,Dazai J,Stewart J,Egan S,Ahmed M,Wong CS,Jaffray DA,Nieman BJ

    更新日期:2018-05-18 00:00:00

  • Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

    abstract::Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou222

    authors: Roth P,Weller M

    更新日期:2014-10-01 00:00:00

  • Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.

    abstract:Background:Glioblastoma cell-initiated vascularization is an alternative angiogenesis called vasculogenic mimicry. However, current knowledge on the mechanism of de novo vessel formation from glioblastoma stem cells (GSCs) is limited. Methods:Sixty-four glioblastoma samples from patients and 10 fluorescent glioma xeno...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox016

    authors: Mei X,Chen YS,Chen FR,Xi SY,Chen ZP

    更新日期:2017-08-01 00:00:00

  • Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning.

    abstract::For gamma knife planning, 2.4-mm-slice MRIs are taken under rigid frame fixation, so tiny tumors become visible. This study evaluated differences in the numbers of brain metastases between conventional contrast-enhanced MRI (6 ± 1 mm slice thickness) taken before patient referral and contrast-enhanced MRI for gamma kn...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq084

    authors: Nagai A,Shibamoto Y,Mori Y,Hashizume C,Hagiwara M,Kobayashi T

    更新日期:2010-11-01 00:00:00

  • Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

    abstract:BACKGROUND:Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time point...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz166

    authors: Bashir A,Mathilde Jacobsen S,Mølby Henriksen O,Broholm H,Urup T,Grunnet K,Andrée Larsen V,Møller S,Skjøth-Rasmussen J,Skovgaard Poulsen H,Law I

    更新日期:2019-12-17 00:00:00

  • A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

    abstract::Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq148

    authors: Yu L,Baxter PA,Zhao X,Liu Z,Wadhwa L,Zhang Y,Su JM,Tan X,Yang J,Adesina A,Perlaky L,Hurwitz M,Idamakanti N,Police SR,Hallenbeck PL,Blaney SM,Chintagumpala M,Hurwitz RL,Li XN

    更新日期:2011-01-01 00:00:00

  • Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.

    abstract:BACKGROUND:We assessed the longitudinal hazard characteristics for death and progression in patients with glioblastoma, evaluated the impact of prognostic factors and treatment on the hazard within different time intervals to determine if effects are time varying, and quantified the influence of progression on survival...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/neuonc/nov009

    authors: Wang M,Dignam JJ,Won M,Curran W,Mehta M,Gilbert MR

    更新日期:2015-07-01 00:00:00

  • Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness.

    abstract:BACKGROUND:Malignant glioma is an aggressive cancer requiring new therapeutic targets. MicroRNAs (miRNAs) regulate gene expression post transcriptionally and are implicated in cancer development and progression. Deregulated expressions of several miRNAs, specifically hsa-miR-184, correlate with glioma development. MET...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou220

    authors: Emdad L,Janjic A,Alzubi MA,Hu B,Santhekadur PK,Menezes ME,Shen XN,Das SK,Sarkar D,Fisher PB

    更新日期:2015-03-01 00:00:00

  • Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.

    abstract:BACKGROUND:Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is implicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to postchemotherapy cognitive impairment. We hypothesized that a single n...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov162

    authors: Ng T,Teo SM,Yeo HL,Shwe M,Gan YX,Cheung YT,Foo KM,Cham MT,Lee JA,Tan YP,Fan G,Yong WS,Preetha M,Loh WJ,Koo SL,Jain A,Lee GE,Wong M,Dent R,Yap YS,Ng R,Khor CC,Ho HK,Chan A

    更新日期:2016-02-01 00:00:00

  • Paraneoplastic chorea: case study with autopsy confirmation.

    abstract::A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/4.3.192

    authors: Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

    更新日期:2002-07-01 00:00:00

  • Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

    abstract:BACKGROUND:Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not327

    authors: Bello L,Riva M,Fava E,Ferpozzi V,Castellano A,Raneri F,Pessina F,Bizzi A,Falini A,Cerri G

    更新日期:2014-08-01 00:00:00

  • A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

    abstract:BACKGROUND:Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective ope...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou126

    authors: de Jongste AH,van Gelder T,Bromberg JE,de Graaf MT,Gratama JW,Schreurs MW,Hooijkaas H,Sillevis Smitt PA

    更新日期:2015-01-01 00:00:00

  • Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

    abstract::Antiangiogenic therapy is associated with increased radiographic responses in glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have been shown to mediate escape from antiangiogenic therapy in preclinical models, we examined the role of macrophages in patients with recurrent glioblastoma...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not082

    authors: Lu-Emerson C,Snuderl M,Kirkpatrick ND,Goveia J,Davidson C,Huang Y,Riedemann L,Taylor J,Ivy P,Duda DG,Ancukiewicz M,Plotkin SR,Chi AS,Gerstner ER,Eichler AF,Dietrich J,Stemmer-Rachamimov AO,Batchelor TT,Jain RK

    更新日期:2013-08-01 00:00:00

  • Invasion patterns in brain metastases of solid cancers.

    abstract:BACKGROUND:Brain metastases are generally considered to be well demarcated from the surrounding brain parenchyma, although infiltrative growth patterns have been observed. We systemically investigated infiltration patterns and expression of adhesion molecules in a large and well-defined series of autopsy cases of brain...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not112

    authors: Berghoff AS,Rajky O,Winkler F,Bartsch R,Furtner J,Hainfellner JA,Goodman SL,Weller M,Schittenhelm J,Preusser M

    更新日期:2013-12-01 00:00:00

  • Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma.

    abstract::Allergies and the use of anti-inflammatory medication appear to be associated with reduced glioblastoma risk. However, these observations may merely reflect systemic immunosuppression induced by the tumor. To better understand the effect of this tumor on allergies and inflammation, we used CD133 mRNA expression as an ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nop035

    authors: Schwartzbaum JA,Huang K,Lawler S,Ding B,Yu J,Chiocca EA

    更新日期:2010-04-01 00:00:00

  • Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

    abstract::PDGFRA is a critical gene in glioma biology. Similar to EGFR, PDGFRA has been shown to be overexpressed, amplified, mutated, or truncated in gliomas, particularly glioblastomas. In addition, PDGFRA has been recently shown to be rearranged in glioblastoma. However, the frequency, cooccurrence, and clinical value of PDG...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos217

    authors: Alentorn A,Marie Y,Carpentier C,Boisselier B,Giry M,Labussière M,Mokhtari K,Hoang-Xuan K,Sanson M,Delattre JY,Idbaih A

    更新日期:2012-11-01 00:00:00

  • Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

    abstract::Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq170

    authors: Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

    更新日期:2011-01-01 00:00:00

  • Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

    abstract::Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm(3). This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/S115285170400119X

    authors: Rege TA,Fears CY,Gladson CL

    更新日期:2005-04-01 00:00:00

  • Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.

    abstract:BACKGROUND:The standard of care for newly diagnosed glioblastoma is maximal safe surgical resection, followed by chemoradiation therapy. We assessed carmustine wafer implantation efficacy and safety when used in combination with standard care. METHODS:Included were adult patients with (n = 354, implantation group) and...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/nov126

    authors: Pallud J,Audureau E,Noel G,Corns R,Lechapt-Zalcman E,Duntze J,Pavlov V,Guyotat J,Hieu PD,Le Reste PJ,Faillot T,Litre CF,Desse N,Petit A,Emery E,Voirin J,Peltier J,Caire F,Vignes JR,Barat JL,Langlois O,Dezamis E

    更新日期:2015-12-01 00:00:00

  • DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

    abstract::We explored the associations of aberrant DNA methylation patterns in 12 candidate genes with adult glioma subtype, patient survival, and gene expression of enhancer of zeste human homolog 2 (EZH2) and insulin-like growth factor-binding protein 2 (IGFBP2). We analyzed 154 primary glioma tumors (37 astrocytoma II and II...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq190

    authors: Zheng S,Houseman EA,Morrison Z,Wrensch MR,Patoka JS,Ramos C,Haas-Kogan DA,McBride S,Marsit CJ,Christensen BC,Nelson HH,Stokoe D,Wiemels JL,Chang SM,Prados MD,Tihan T,Vandenberg SR,Kelsey KT,Berger MS,Wiencke JK

    更新日期:2011-03-01 00:00:00

  • ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

    abstract::Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor. Conventional treatment options include surgery and radiotherapy but there is no validated medical option. Recent evidence suggests that Merlin deficiency may r...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq012

    authors: Ammoun S,Cunliffe CH,Allen JC,Chiriboga L,Giancotti FG,Zagzag D,Hanemann CO,Karajannis MA

    更新日期:2010-08-01 00:00:00